Meta-analysis on prevalence and attribution of human papillomavirus types 52 and 58 in cervical neoplasia worldwide

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Chan, Paul K S ^a   Ho, Wendy C S ^a   Chan, Martin C W ^a   Wong, Martin C S ^b   Yeung, Apple C M ^a   Chor, Josette S Y ^b   Hui, Mamie ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Prince of Wales Hospital   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADENOSQUAMOUS CARCINOMA; ARTICLE; ATTRIBUTABLE RISK; CHINESE; ENGLISHMAN; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; INJURY SEVERITY; PACIFIC ISLANDS; PAPILLOMAVIRUS INFECTION; PREVALENCE; SYSTEMATIC REVIEW; TUMOR INVASION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; CANCER GRADING; CANCER STAGING; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLASSIFICATION; COMPLICATION; FACTUAL DATABASE; FEMALE; HEALTH; META ANALYSIS; PAPILLOMAVIRIDAE; PATHOLOGY; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

HUMAN PAPILLOMAVIRUS TYPES;

CERVICAL INTRAEPITHELIAL NEOPLASIA; DATABASES, FACTUAL; FEMALE; GLOBAL HEALTH; HUMANS; NEOPLASM GRADING; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; UTERINE CERVICAL NEOPLASMS;

EID: 84907212837     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107573     Document Type: Article

References (34)

1. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Database: International Agency for Research on Cancer. Available: http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx. Accessed 31 July 2014
2. Walboomers JM, Jacobs MV, Manos MM, Bosch EX, Kummer JA, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1): 12-19.
3. A review of human carcinogens. Part B: Biological agents/IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2009: Lyon, France). Available: http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B.pdf
4. de Sanjose S, Quint WG, Alemany L, Geraets DT, Retrospective International Survey and HPV Time Trends Study Group, et al. (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11(11): 1048-1056.
5. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM (2011) Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 128(4): 927-935.
6. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, et al. (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta analysis update. Int J Cancer 121(3): 621-632.
7. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, et al. (2008) Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26 Suppl 10: K1-K16.
8. Chan PK, Li WH, Chan MY, Ma WL, Cheung JL, et al. (1999) High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions. J Med Virol 59(2): 232-238.
9. Chan PK, Cheung TH, Tam AO, Lo KW, Yim SF, et al. (2006) Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer 118(1): 243-245.
10. Chan PK, Ho WC, Yu MY, Pong WM, Chan AC, et al. (2009) Distribution of human papillomavirus types in cervical cancers in Hong Kong: current situation and changes over the last decades. Int J Cancer 125(7): 1671-1677.
11. Chan PK, Cheung TH, Li WH, Yu MY, Chan MY, et al. (2012) Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in Southern China. Int J Cancer 131(3): 692-705.
12. Huang S, Afonina I, Miller BA, Beckmann AM (1997) Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Int J Cancer 70(4): 408-411.
13. Liaw KL, Hsing AW, Chen CJ, Schiffman MH, Zhang TY, et al. (1995) Human papillomavirus and cervical neoplasia: a case control study in Taiwan. Int J Cancer 62(5): 565-571.
14. Hwang T (1999) Detection and typing of human papillomavirus DNA by PCR using consensus primers in various cervical lesions of Korean women. J Korean Med Sci 14(6): 593-599.
15. Asato T, Maehama T, Nagai Y, Kanazawa K, Uezato H, et al. (2004) A large case-control study of cervical cancer risk associated with human papillomavirus infection in Japan, by nucleotide sequencing-based genotyping. J Infect Dis 189 (10): 1829-1832.
16. Insinga RP, Liaw KL, Johnson LG, Madeleine MM (2008) A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 17(7): 1611-1622.
17. Newcombe RG (1998) Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17(8): 857-872.
18. Wilson EB (1927) Probable Inference, the Law of Succession, and Statistical Inference. J Am Stat Assoc 22: 209-212.
19. Williamson D, Nagappan R, Sirikonda R, Rahnama F, Thomas S, et al. (2011) Distribution of HPV genotypes in women with cervical cancer in Auckland, New Zealand; a review of 50 specimens between 2000-2006. Aust NZJ Obstet Gynaecol 51(1): 67-70.
20. Liu J, Rose B, Huang X, Liao G, Carter J, et al. (2004) Comparative analysis of characteristics of women with cervical cancer in high-versus low-incidence regions. Gynecol Oncol 94(3): 803-810.
21. Stevens MP, Garland SM, Tan JH, Quinn MA, Petersen RW, et al. (2009) HPV genotype prevalence in women with abnormal pap smears in Melbourne, Australia. J Med Virol 81(7): 1283-1291.
22. Stevens MP, Tabrizi SN, Quinn MA, Garland SM (2006) Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia. Int J Gynecol Cancer 16(3): 1017-1024.
23. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, et al. (2012) Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 131: 2349-2359.
24. Chan PK, Cheung JL, Cheung TH, Lin CK, Siu SS, et al. (2007) HLA-DQB1 polymorphisms and risk for cervical cancer: a case-control study in a southern Chinese population. Gynecol Oncol 105(3): 736-741.
25. Chan PK, Cheung JL, Cheung TH, Lin CK, Tam AO, et al. (2006) HLA-B alleles, high-risk HPV infection and risk for cervical neoplasia in southern Chinese women. Int J Cancer 118(6): 1430-1435.
26. Chan PK, Luk AC, Park JS, Smith-McCune KK, Palefsky JM, et al. (2011) Identification of human papillomavirus type 58 lineages and the distribution worldwide. J Infect Dis 203: 1565-1573.
27. Zhang C, Park JS, Grce M, Hibbitts S, Palefsky JM, et al. (2014) Geographical Distribution and Risk Association of Human Papillomavirus Genotype 52-Variant Lineages. J Infect Dis: In press.
28. Herrero R (2009) Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis 199: 919-922.
29. Brown DR, Kjaer SK, Sigurdson K, Iversen OE, Hernandez-Avila M, et al. (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 199: 926-935.
30. Wheeler CM, Kjaer SK, Sigurdson K, Iversen OE, Hernandez-Avila M, et al. (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV Types in sexually active women aged 16-26 years. J Infect Dis 199: 936-944.
31. De Vincenzo R, Ricci C, Conte C, Scambia G (2013) HPV vaccine cross-protection: Highlights on additional clinical benefit. Gynecol Oncol 130: 642-651.
32. Chan PK, Lam CW, Cheung TH, Li WW, Lo KW, et al. (2002) Association of human papillomavirus type 58 variant with the risk of cervical cancer. J Natl Cancer Inst 94(16): 1249-1253.
33. Chan PK, Zhang C, Park JS, Smith-McCune KK, Palefsky JM, et al. (2013) Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations. Int J Cancer 132(11): 2528-2536.
34. Sánchez-Lander J, Cortiñas P, Loureiro CL, Pujol FH, Medina F, et al. (2012) Human papillomavirus in invasive cervical cancer and cervical intraepithelial neoplasia 2 and 3 in Venezuela: a cross-sectional study. Cancer Epidemiol 36(5): e284-287.